{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:25:10Z","timestamp":1655943910046},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1016\/j.ygyno.2007.04.011","type":"journal-article","created":{"date-parts":[[2007,5,23]],"date-time":"2007-05-23T11:54:13Z","timestamp":1179921253000},"page":"375-380","source":"Crossref","is-referenced-by-count":7,"title":["Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction"],"prefix":"10.1016","volume":"106","author":[{"given":"Yanfang","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin W.","family":"Finkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2007.04.011_bib1","doi-asserted-by":"crossref","DOI":"10.1111\/j.1525-1438.2007.00847.x","article-title":"Systemic anticancer therapy in gynecologic cancer patients with renal dysfunction","author":"Li","year":"2007","journal-title":"Int J Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2007.04.011_bib2","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2007.04.011_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/j.seminoncol.2004.08.010","article-title":"Efficacy and safety of liposomal anthracyclines in phase I\/II clinical trials","volume":"31","author":"Alberts","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ygyno.2007.04.011_bib4","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1006\/gyno.2000.5980","article-title":"The clinical utility of liposomal doxorubicin in recurrent ovarian cancer","volume":"81","author":"Campos","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2007.04.011_bib5","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2004.12.057","article-title":"Skin toxicity associated with pegylated liposomal doxorubicin (40\u00a0mg\/m2) in the treatment of gynecologic cancers","volume":"97","author":"Kim","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2007.04.011_bib6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1006\/gyno.2001.6272","article-title":"Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages","volume":"82","author":"Rose","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2007.04.011_bib7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ygyno.2007.04.011_bib8","series-title":"Anticancer drug toxicity: prevention, management and clinical pharmacokinetics","article-title":"Anthracyclines and other intercalating agents","author":"Lipp","year":"1999"},{"key":"10.1016\/j.ygyno.2007.04.011_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.ygyno.2007.04.011_bib10","first-page":"925","article-title":"Automated reporting of GFR-coming soon to a laboratory near you!","volume":"34","author":"Johnson","year":"2005","journal-title":"Aust Fam Physician"},{"key":"10.1016\/j.ygyno.2007.04.011_bib11","unstructured":"The National Kidney Foundation Kidney and Dialysis Outcomes Quality Initiative (K\/DOQI) guidelines. Available from URL: http:\/\/www.kidney.org\/professionals\/kdoqi\/guidelines_ckd\/toc.htm. 2001. Accessed on 12\/10\/06."},{"key":"10.1016\/j.ygyno.2007.04.011_bib12","unstructured":"The NCI common toxicity criteria version 2. Available from URL: http:\/\/ctep.info.nih.gov\/reporting\/ctc_archive.html. 1999. Accessed on 12\/10\/06."},{"key":"10.1016\/j.ygyno.2007.04.011_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2007.04.011_bib14","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/92.18.1534","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup","volume":"92","author":"Vergote","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2007.04.011_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/JCO.2005.01.2757","article-title":"Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide","volume":"24","author":"Rustin","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2007.04.011_bib16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1006\/gyno.2000.5921","article-title":"Phase 2 trial of liposomal doxorubicin (40\u00a0mg\/m(2)) in platinum\/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum","volume":"78","author":"Markman","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2007.04.011_bib17","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00432-003-0497-8","article-title":"Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer","volume":"129","author":"Escobar","year":"2003","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ygyno.2007.04.011_bib18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1634\/theoncologist.10-3-205","article-title":"Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer","volume":"10","author":"Rose","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2007.04.011_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.seminoncol.2004.08.004","article-title":"Liposomal anthracycline treatment for ovarian cancer","volume":"31","author":"Markman","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ygyno.2007.04.011_bib20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ygyno.2005.11.048","article-title":"Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"102","author":"Rose","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2007.04.011_bib21","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.ejca.2005.12.011","article-title":"A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)","volume":"42","author":"Coleman","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2007.04.011_bib22","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z","article-title":"Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma","volume":"89","author":"Lyass","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2007.04.011_bib23","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","article-title":"Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation","volume":"15","author":"Muggia","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2007.04.011_bib24","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2007.04.011_bib25","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2000.18.17.3093","article-title":"Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer","volume":"18","author":"Gordon","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2007.04.011_bib26","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/annonc\/mdl079","article-title":"Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial","volume":"17","author":"Sehouli","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2007.04.011_bib27","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1023\/A:1008365716693","article-title":"Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500\u00a0mg\/m2","volume":"11","author":"Safra","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2007.04.011_bib28","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1023\/A:1008216430806","article-title":"The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin","volume":"9","author":"Berry","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2007.04.011_bib29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1053\/j.seminoncol.2004.08.006","article-title":"Cardiac safety of liposomal anthracyclines","volume":"31","author":"Ewer","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ygyno.2007.04.011_bib30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ygyno.2004.03.024","article-title":"Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies","volume":"94","author":"Uyar","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2007.04.011_bib31","article-title":"Decreased risk of cardiotoxicity with long-term use of Doxil\/Caelyx at high lifetime cumulative doses in patients with AIDA-related Kaposi's sarcoma (KS)","volume":"20","author":"Mustafa","year":"2001","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825807002685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825807002685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,28]],"date-time":"2019-04-28T07:19:05Z","timestamp":1556435945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825807002685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S0090825807002685"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2007.04.011","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}